icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
hLheNVuhr5Qy5g7B
Listen
